Skip to main content
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
How Care Works
Virtual & Home Visits
Virtual care across 40 states + house calls in Philadelphia
Concierge vs. Direct Care
Zero visit copays, zero hidden fees, relationship model
Send Medical Records
Securely upload prior labs & notes before consultation
Common Questions (FAQ)
PCP scope, insurance, labs & cancellation policies
Services
Primary Care & Acute Visits
Same-day sick visits, refills & comprehensive PCP care
Chronic & Complex Care
POTS, MCAS, Long COVID, Lyme & fatigue workups
Hormones & Endocrine
TRT, thyroid, perimenopause, menopause & PCOS
Metabolic Health & Weight
Advanced lipid testing, GLP-1s & glucose monitoring
Longevity & Prevention
Medicine 3.0 baselines, VO2 max, DEXA & prevention
All Clinical Services
Comprehensive catalogue of 36+ clinical services
Membership
Membership Details
Unlimited direct access, continuous physician care
Care Packages
The Reset & Strategic Roadmap evaluations
Billing & Payment FAQ
HSA/FSA eligibility, transparent cancellation policy
About
Meet Dr. Ash
Your Physician
GER·O·SPAN
Our Clinical Framework
Clinical Library & Articles
Evidence-based health guides reviewed by Dr. Ash
What People Say
124 patient reviews across 6 platforms
Contact Dr. Ash
Reach out with questions or book an intro
Patient PortalStart Intake
Hydroxyzine for Sleep: Why Sedation Fades While Risks Stay
Fishtown Medicine•11 min read
4.96 (124)

Hydroxyzine for Sleep: Why Sedation Fades While Risks Stay

Ashvin Vijayakumar MD

Medically Reviewed

Ashvin Vijayakumar MD•Updated November 8, 2026
On This Page
  • What do sleep guidelines say about hydroxyzine vs. CBT-I?
  • What do human clinical trials show (Hydroxyzine vs. Placebo and CBT-I)?
  • Why does hydroxyzine stop helping you sleep within days while next-day driving risk stays high?
  • What are the heart rhythm (QTc), anticholinergic (Beers Criteria), and skin risks?
  • 1. QTc Prolongation and Torsades de Pointes (FDA Label 2025/2026; EMA PRAC 2015)
  • 2. Anticholinergic Burden & Cumulative Dementia Cohorts (AGS Beers Criteria 2023; Gray 2015; Coupland 2019)
  • 3. Rare Pustular Skin Rash (AGEP) & Cetirizine Cross-Sensitivity (FDA Label)
  • How does hydroxyzine compare with better sleep options?
  • Guidance from the Clinic
  • Actionable Steps
  • Common Questions
  • What dose of hydroxyzine is used for sleep, and what is the maximum safe limit?
  • Why does hydroxyzine stop working for sleep after a few nights?
  • Does hydroxyzine impair morning driving the next day?
  • Which medications interact with hydroxyzine (QTc and CNS depressants)?
  • Deep Questions
  • Why did AASM, ACP, and VA/DoD all decline to recommend hydroxyzine for insomnia?
  • How strong is the link between chronic anticholinergic sleep aids and dementia (Gray 2015; Coupland 2019)?
  • Why is low-dose doxepin (3 to 6 mg) preferred over hydroxyzine when an H1 blocker is indicated?
  • ✦Key Takeaways
  • Related at Fishtown Medicine
  • Scientific References

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR30-second take

No major sleep guideline (AASM 2017/2021, ACP 2016, or VA/DoD 2019/2025) recommends hydroxyzine for chronic insomnia, and zero randomized trials have tested it in diagnosed chronic insomnia disorder or against first-line CBT-I (very low evidence certainty; 5 small studies totaling 207 adults, Burgazli 2023). While H1-receptor sedation often fades within 3 to 4 days (Richardson 2002), hydroxyzine's 20-hour half-life causes next-day driving impairment equal to a 0.08% blood alcohol concentration on Day 1 and 0.05% on Day 8 (Conen 2011; crash responsibility OR 1.67 to 2.60 in Orriols 2017). It also carries FDA and EMA warnings for QTc prolongation and torsades de pointes and a strong AGS Beers Criteria (2023) recommendation to avoid in adults 65 and older due to anticholinergic delirium, fall, and cumulative dementia risk.

TL;DR: Hydroxyzine (Atarax, Vistaril, 10 to 50 mg off-label at bedtime) is an old allergy and anxiety drug often prescribed for sleep because it is not a controlled substance. Clinical trials show a sharp mismatch between its fading sleep benefit and its lingering harms:

  1. Zero guideline endorsement (AASM, ACP, VA/DoD) and very low evidence certainty (Burgazli 2023): No major guideline recommends hydroxyzine for insomnia. Across the medical literature, only 5 small studies (207 patients total) have tested hydroxyzine for sleep. Zero RCTs have enrolled adults with chronic insomnia disorder or compared it with CBT-I. By contrast, multicomponent CBT-I holds a strong first-line recommendation (SOL -19 min, WASO -26 min, lasting at 12 months).
  2. The H1 tolerance vs. next-day driving trap (Richardson 2002; Conen 2011; Orriols 2017): Histamine H1 sedation fades fast (3 to 4 days in Richardson 2002), yet hydroxyzine has a ~20-hour half-life. In an on-road driving RCT (Conen et al., 2011), 50 mg of hydroxyzine caused lane weaving equal to a 0.08% blood alcohol level on Day 1 and still equal to 0.05% on Day 8. In a study of 142,771 drivers (Orriols 2017), hydroxyzine raised at-fault crash odds by 67% to 160% (OR 1.67 to 2.60).
  3. Heart rhythm (QTc / torsades) and Beers Criteria anticholinergic harms (EMA 2015; FDA 2025/2026; Beers 2023): Both the FDA and European regulators (EMA) warn that hydroxyzine stretches the QTc interval and can trigger torsades de pointes. It is contraindicated in heart disease or with QT-stretching drugs (citalopram, escitalopram, fluoroquinolones, macrolides, or ondansetron). The 2023 AGS Beers Criteria strongly advise avoiding hydroxyzine in adults >= 65 due to confusion, falls, and dementia risk (Gray 2015; Coupland 2019).

A 43-year-old nurse from Northern Liberties came into my Fishtown clinic after taking 50 mg of hydroxyzine at 11:00 PM every night for six months alongside 20 mg of escitalopram (Lexapro). Her bedtime drowsiness had worn off after the first week. She still lay awake past 1:00 AM at night, yet felt so heavy-lidded at 7:00 AM that she drifted onto the I-95 rumble strip driving to her hospital shift. We checked a baseline ECG (since hydroxyzine and escitalopram both stretch the QTc interval), stopped the nightly hydroxyzine, and guided her through a four-week CBT-I sleep consolidation plan. Her morning lane-drifting vanished in two days, and her sleep latency dropped below 20 minutes by week three.

What do sleep guidelines say about hydroxyzine vs. CBT-I?

No major sleep guideline (AASM 2017/2021, ACP 2016, or VA/DoD 2019/2025) recommends hydroxyzine for chronic or short-term insomnia. Every guideline recommends multicomponent CBT-I as strong first-line care (moderate certainty), while warning against sedating antihistamines (very low to low certainty).12345

Guideline BodyMulticomponent CBT-I StatusHydroxyzine StatusClosest Antihistamine Ruling (Diphenhydramine)
AASM Pharmacologic (Sateia et al., JCSM 2017) & Behavioral (Edinger et al., JCSM 2021)STRONG recommendation for CBT-I first-line (moderate certainty, 49 RCTs).2Not reviewed; no recommendation (lack of insomnia RCT data).1WEAK recommendation AGAINST diphenhydramine (50 mg) for sleep onset or stay-asleep care (low certainty; no meaningful gain).1
American College of Physicians (Qaseem et al., Ann Intern Med 2016)STRONG recommendation for CBT-I as first treatment (moderate certainty).3Not named; antihistamines noted only as off-label.3First-generation antihistamines and trazodone listed as lacking sufficient study.3
VA/DoD Insomnia & OSA Guidelines (Mysliwiec 2020; Sharafkhaneh 2025)STRONG recommendation for CBT-I (moderate certainty) over drugs first-line.45No studies met inclusion rules for antihistamines.45WEAK recommendation AGAINST antihistamines (very low confidence), citing tolerance within 3 to 4 days and anticholinergic harm.45

Why the guideline silence matters: No society found qualifying chronic-insomnia RCTs of hydroxyzine to grade. Applying standard GRADE rules (downgrading for wrong study groups, tiny samples, and bias) places the certainty of evidence for hydroxyzine in insomnia at very low.156

What do human clinical trials show (Hydroxyzine vs. Placebo and CBT-I)?

A 2023 systematic review (Burgazli et al., Hum Psychopharmacol 2023) found only 5 small studies (4 RCTs and 1 open-label study; 207 adults total) testing hydroxyzine (25 to 100 mg) for sleep. Zero trials enrolled patients with chronic insomnia disorder, zero lasted past a few weeks, and zero compared hydroxyzine with CBT-I.67

Study / PopulationDesign & Sample (n)Dose & DurationSleep Outcome vs. Placebo or ControlDocumented Harms & Limits
Healthy Volunteers (Alford et al., Hum Psychopharmacol 2004)Double-blind crossover RCT (n = 12)Single night: 25 mg or 50 mg vs placeboCut sleep-onset latency (SOL) from 16.6 min to 7.2 min (-9.4 min; -57%); total sleep (TST) +24.5 min at 25 mg only; zero change in deep sleep.67Next-day objective drowsiness in women; tested healthy sleepers (16.6 min baseline SOL), not insomnia patients.7
Cirrhosis + Minimal Hepatic Encephalopathy (Spahr et al., Am J Gastroenterol 2007)Double-blind parallel RCT (n = 35)25 mg at bedtime for 10 daysSubjective sleep improved in 40% vs 0%; >= 30% actigraphy efficiency gain in 65% vs 25% (p < 0.04).8Caused overt liver encephalopathy in 1 patient (hydroxyzine is cleared by the liver); 10-day trial only.8
Dysthymia on SSRIs (Kotan et al., 2015, in Burgazli 2023)Randomized trialBedtime hydroxyzine vs placeboWorsened sleep: falling asleep took +14.7 minutes longer and total sleep dropped by ~80 minutes vs placebo.6Shows hydroxyzine can worsen sleep in adults taking SSRI antidepressants.6
PTSD Nightmares (Ahmadpanah et al., 2014, in Burgazli 2023)Randomized trial (8 weeks)100 mg at bedtime vs prazosin vs placeboImproved PSQI score and cut nightmares vs placebo (less helpful than prazosin).6Trauma cohort; 100 mg hits the maximum adult QTc safety ceiling.6
Comparator Benchmark: Multicomponent CBT-I (Trauer et al., Ann Intern Med 2015; Gao et al., 2022; Morin & Buysse, NEJM 2024)20 RCT meta-analysis (n = 1,162) & 61 RCT network (n = 11,571)4 to 8 sessions (in-person or digital)SOL -19.0 min (95% CI -14.1 to -23.9), WASO -26.0 min (-15.5 to -36.5), sleep efficiency +9.9%; 60% to 70% response and 40% to 45% remission at 12 months.91011Across 23 head-to-head RCTs vs sleep pills (Zhang 2022; Perlis Lancet 2022), only CBT-I keeps working after treatment ends.1213

Why does hydroxyzine stop helping you sleep within days while next-day driving risk stays high?

First-generation H1 sedation tolerance builds within 3 to 4 days (Richardson et al., J Clin Psychopharmacol 2002), and hydroxyzine's FDA label notes that subjective drowsiness often fades after a few days. However, its 20.0 +/- 4.1 hour adult half-life (29.3 +/- 10.1 hours in older adults, Simons 1984/1989) keeps increasing next-day somnolence (Staevska 2014) and highway lane weaving (Conen 2011; Orriols 2017).141516173435

Three-column clinical diagram of Hydroxyzine for Sleep vs. CBT-I: Column 1 shows the H1 Sedation vs. Driving Mismatch (H1 sedation tolerance develops within 3 to 4 days [Richardson 2002], with only 5 small studies totaling 207 adults [Burgazli 2023] and 0 RCTs in chronic insomnia disorder, while hydroxyzine's ~20-hour half-life causes on-road lane weaving equal to 0.08% BAC on Day 1 and 0.05% BAC on Day 8 [Conen 2011] and raises crash responsibility odds to OR 1.67-2.60 [Orriols 2017]); Column 2 details Three Documented Harms (QTc prolongation and torsades de pointes [FDA label & EMA 2015 PRAC contraindication in cardiovascular disease or with QTc drugs], Strong Anticholinergic Burden [AGS Beers Criteria 2023 Strong Avoid in age >=65, cumulative dementia risk in Gray 2015 / Coupland 2019], and Paradoxical Worsening in SSRI/dysthymia [Kotan 2015]); Column 3 outlines Better Alternatives by Clinical Goal (First-Line Multicomponent CBT-I [Strong recommendation in AASM 2021, ACP 2016, VA/DoD 2025; SOL -19 min, WASO -26 min] and Low-Dose Doxepin 3-6 mg for sleep maintenance).
Why H1 receptor sedation fades within days while next-day driving impairment, QTc prolongation, and anticholinergic burden persist.
  1. Rapid H1 sedation tolerance vs. nighttime sleep (Richardson 2002; FDA Label; Staevska 2014): In the classic H1 tolerance study (Richardson et al., 2002, n = 15 taking diphenhydramine 50 mg twice daily), daytime sleepiness on nap tests and self-report matched placebo by Day 4.14 For hydroxyzine, the FDA label notes that subjective drowsiness may fade after a few days.2122 In a crossover trial of bedtime dosing (Staevska et al., Br J Dermatol 2014, n = 24), hydroxyzine 50 mg at night increased next-day sleepiness without improving sleep over a nonsedating antihistamine.35
  2. Long half-life and highway driving risk (Simons 1984/1989; Goetz 1989; Conen et al., J Psychopharmacol 2011): Feeling less sleepy does not mean safe driving. Elimination studies (Simons et al., JACI 1984 & Clin Pharmacol Ther 1989) measured hydroxyzine's half-life at 20.0 +/- 4.1 hours in young adults and 29.3 +/- 10.1 hours in older adults.34 In a crossover trial (Goetz et al., JACI 1989, n = 16), twice-daily hydroxyzine (25 mg) slowed reaction times across all 5 days.15 In a highway-driving RCT (Conen et al., J Psychopharmacol 2011), 50 mg of hydroxyzine increased lane weaving (SDLP) by +4.7 cm on Day 1 (matching a 0.08% blood alcohol level) and by +2.2 cm on Day 8 (matching a 0.05% blood alcohol level) - even when drivers felt alert.16
  3. Traffic crash risk (Orriols et al., Accid Anal Prev 2017; Bierly & D'Orazio, J Anal Toxicol 2025): In a French study of 142,771 injury crashes (Orriols et al., 2017), filling a hydroxyzine prescription raised at-fault crash odds by 67% (OR 1.67, 95% CI 1.22 to 2.30), rising to OR 2.60 (160% higher odds) at highest exposure.17 By 2023, hydroxyzine passed diphenhydramine as the top antihistamine found in US impaired-driving blood tests (Bierly & D'Orazio, 2025).20

What are the heart rhythm (QTc), anticholinergic (Beers Criteria), and skin risks?

Hydroxyzine carries FDA and EMA warnings for QTc prolongation and torsades de pointes, a strong 2023 AGS Beers Criteria rule to avoid in adults 65 and older due to delirium and falls, and an FDA warning for severe pustular skin rash (AGEP).18212223

1. QTc Prolongation and Torsades de Pointes (FDA Label 2025/2026; EMA PRAC 2015)

Hydroxyzine blocks heart hERG potassium channels at higher blood levels, slowing heart recovery:

  • Heart safety rules (EMA 2015; Morales 2021; Morrow 2022; Ali FAERS 2021): After reports of QT prolongation and torsades de pointes (Ali et al., Expert Opin Drug Saf 2021), European (EMA PRAC 2015), UK, and Canadian regulators barred hydroxyzine in anyone with known QT prolongation, heart disease, family history of sudden cardiac death, slow heart rate (bradycardia), or low potassium/magnesium.2122232425 Regulators also capped total daily doses at 100 mg/day in adults and 50 mg/day in older adults.2326 New starts in heart patients dropped right away (-46.2 per 100,000 in Scotland and -36.5 in England, Morales et al., 2021).23
  • Drug interactions that raise QTc risk (FDA Label): Do not combine hydroxyzine with other QT-stretching drugs. That list includes heart-rhythm drugs (quinidine, procainamide, amiodarone, sotalol), citalopram or escitalopram, antipsychotics (haloperidol, quetiapine, ziprasidone), fluoroquinolones (ciprofloxacin, moxifloxacin), macrolides (azithromycin, erythromycin), ondansetron, and methadone.2122

2. Anticholinergic Burden & Cumulative Dementia Cohorts (AGS Beers Criteria 2023; Gray 2015; Coupland 2019)

In lab assays (Orzechowski et al., Eur J Pharmacol 2005), hydroxyzine has less antimuscarinic activity than diphenhydramine, yet it still causes dry mouth, urinary retention, and confusion in older adults:1836

  • 2023 AGS Beers Criteria (Strong Avoid in Age >= 65): The American Geriatrics Society lists hydroxyzine alongside diphenhydramine and doxylamine as a first-generation antihistamine to avoid in older adults. It also gives a strong rule against combining two or more anticholinergic drugs.18 Short-term harms include dry mouth, constipation, blurry vision, trouble urinating, delirium, and falls.18
  • Long-term dementia cohorts (Gray et al., JAMA Intern Med 2015; Richardson et al., BMJ 2018; Coupland et al., JAMA Intern Med 2019): In Gray et al. (2015) (n = 3,434), > 1,095 daily doses of strong anticholinergics over 10 years was linked with a 54% higher dementia risk (HR 1.54; Alzheimer's HR 1.63).27 In two UK case-control studies (Richardson et al., BMJ 2018, 40,770 cases; Coupland et al., JAMA Intern Med 2019, 58,769 cases), strong anticholinergic exposure raised dementia odds (OR 1.49), driven by anticholinergic antidepressants (OR 1.29), bladder drugs, and Parkinson drugs (OR 1.14 non-significant for prescribed antihistamines).2829 Observational cohorts show association instead of drug-specific causation. Still, skipping nightly anticholinergic sleep pills is an easy win when safer options exist.

Evidence-Based Treatment

Dr. Ash reviews the research - and applies it to your specific biology.

Book a Consultation

3. Rare Pustular Skin Rash (AGEP) & Cetirizine Cross-Sensitivity (FDA Label)

Hydroxyzine breaks down in the liver into cetirizine (Zyrtec). The FDA label warns that hydroxyzine can rarely cause a severe pustular rash (AGEP). Anyone with a prior rash to hydroxyzine, cetirizine, or levocetirizine should avoid all three drugs.2122

How does hydroxyzine compare with better sleep options?

  1. Against Multicomponent CBT-I (First-Line for Chronic Insomnia): CBT-I wins on every measure. Across 49+ RCTs (Edinger 2021; Trauer 2015; Scott JAMA Intern Med 2025; Bai 2024; Xu 2024), CBT-I cuts time to fall asleep by 19 minutes and night waking by 26 minutes.29303132 It keeps 40% to 45% of patients in remission a year later with zero QTc, driving, or anticholinergic cost.
  2. Against Low-Dose Doxepin (3 to 6 mg) (When an H1 Blocker Is Wanted for Sleep Maintenance): At 3 to 6 mg, doxepin selectively blocks H1 receptors with minimal anticholinergic effect.1 It holds FDA approval for staying asleep and carries an AASM 2017 recommendation.1
  3. Against Dual Orexin Blockers (Lemborexant, Daridorexant): Orexin blockers quiet wake signals without anticholinergic load, QTc risk, or sleep apnea worsening (Kishi et al., 2026).33

Guidance from the Clinic

Dr. Ash
"When a patient tells me they have taken hydroxyzine every night for years, I ask whether it still helps them fall asleep. Almost always the answer is 'not really, but I'm afraid to stop.' That is the classic H1 antihistamine trap. The sleep sedation fades within four days, while the 20-hour half-life keeps impairing morning driving, adding to your anticholinergic load, and stretching the QTc interval. If you need a short bridge for acute stress, a few nights at 10 to 25 mg is reasonable in a healthy younger adult. For ongoing sleep trouble, we switch to CBT-I first and save targeted, non-anticholinergic options for people who still need medication support."

Actionable Steps

How to audit and replace nightly hydroxyzine safely:

  1. Check the Hard Stop List (QTc, Heart Disease, Age >= 65, Liver Disease): Skip hydroxyzine if you have a long QTc, heart disease (EMA 2015), cirrhosis (Spahr 2007), narrow-angle glaucoma, urinary retention, are 65 or older (Beers 2023), or take QT-stretching drugs (citalopram, escitalopram, ondansetron, fluoroquinolones, macrolides).
  2. Keep Any Situational Use to <= 3 to 7 Nights at 10 to 25 mg: H1 sedation tolerance builds within 3 to 4 days (Richardson 2002), and 50 mg causes next-day lane weaving equal to 0.05% to 0.08% blood alcohol (Conen 2011). Avoid raising the dose when it stops working.
  3. Leave at Least 10 to 12 Hours Before Driving: With a ~20-hour half-life, taking hydroxyzine at midnight leaves high drug levels in your bloodstream during your morning drive (Orriols 2017 crash OR 1.67 to 2.60).
  4. Screen for Obstructive Sleep Apnea Before Using Any Sedative: Morning grogginess and unrefreshing sleep often point to untreated sleep apnea instead of primary insomnia.
  5. Move Chronic Insomnia to CBT-I: If you have taken hydroxyzine or diphenhydramine for months, start an intake with Dr. Ash so we can step down the antihistamine and build a lasting CBT-I plan.
✦

Key Takeaways

  1. No major guideline (AASM 2017/2021, ACP 2016, VA/DoD 2019/2025) recommends hydroxyzine for chronic insomnia, and zero RCTs have tested it in chronic insomnia disorder (very low certainty across 5 small studies / n = 207, Burgazli 2023).1356
  2. Multicomponent CBT-I is the strong first-line recommendation across all guidelines (SOL -19 min, WASO -26 min, 60% to 70% response lasting at 12 months, Trauer 2015; Edinger 2021).2911
  3. Sedation fades within 3 to 4 days (Richardson 2002), while next-day driving risk stays high (~20-hour half-life): 50 mg caused lane weaving equal to 0.08% BAC on Day 1 and 0.05% BAC on Day 8 (Conen 2011), with 1.67x to 2.60x higher at-fault crash odds (Orriols 2017).141617
  4. Screen out QTc risk factors and older age (>= 65): Hydroxyzine carries FDA and EMA warnings for QTc prolongation / torsades de pointes (Morales 2021; Ali 2021) and a 2023 AGS Beers Criteria strong recommendation to avoid due to delirium, falls, and dementia risk.18212327

Related at Fishtown Medicine

  • CBT-I for insomnia
  • Sleeping pills comparison guide
  • Gabapentin for sleep
  • Doxepin for sleep
  • Doxepin (3-6 mg) vs. hydroxyzine (25-50 mg) for sleep
  • Trazodone for sleep
  • Is it insomnia or sleep apnea?
  • Insomnia

Scientific References

  1. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline." Journal of Clinical Sleep Medicine. 2017;13(2):307-349. PMC
  2. Edinger JD, Arnedt JT, Bertisch SM, et al. "Behavioral and Psychological Treatments for Chronic Insomnia Disorder in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline." Journal of Clinical Sleep Medicine. 2021;17(2):255-262. PMC
  3. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. "Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians." Annals of Internal Medicine. 2016;165(2):125-133. DOI
  4. Mysliwiec V, Martin JL, Ulmer CS, et al. "The Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea: Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines." Annals of Internal Medicine. 2020;172(5):325-336. PubMed
  5. Sharafkhaneh A, Thomas A, Ulmer C, et al. "VA/DoD Clinical Practice Guideline for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea (Insomnia/OSA)." Department of Veterans Affairs & Department of Defense. 2025. Guideline PDF
  6. Burgazli CR, Rana KB, Brown JN, Tillman F. "Efficacy and safety of hydroxyzine for sleep in adults: Systematic review." Human Psychopharmacology. 2023;38(2):e2864. DOI
  7. Alford C, Rombaut N, Jones J, Foley S, Idzikowski C, Hindmarch I. "Acute effects of hydroxyzine on nocturnal sleep and sleep tendency the following day: A C-EEG study." Human Psychopharmacology: Clinical and Experimental. 1992;7(1):25-35. DOI
  8. Spahr L, Coeytaux A, Giostra E, Hadengue A, Annoni JM. "Histamine H1 Blocker Hydroxyzine Improves Sleep in Patients With Cirrhosis and Minimal Hepatic Encephalopathy: A Randomized Controlled Pilot Trial." The American Journal of Gastroenterology. 2007;102(4):744-753. PubMed
  9. Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. "Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-Analysis." Annals of Internal Medicine. 2015;163(3):191-204. PubMed
  10. Gao Y, Ge L, Liu M, et al. "Comparative Efficacy and Acceptability of Cognitive Behavioral Therapy Delivery Formats for Insomnia in Adults: A Systematic Review and Network Meta-Analysis." Sleep Medicine Reviews. 2022;64:101648. PubMed
  11. Morin CM, Buysse DJ. "Management of Insomnia." The New England Journal of Medicine. 2024;391(3):247-258. DOI
  12. Zhang Y, Ren R, Yang L, et al. "Comparative Efficacy and Acceptability of Psychotherapies, Pharmacotherapies, and Their Combination for the Treatment of Adult Insomnia: A Systematic Review and Network Meta-Analysis." Sleep Medicine Reviews. 2022;65:101687. PubMed
  13. Perlis ML, Posner D, Riemann D, Bastien CH, Teichtenberg L, Thase M. "Insomnia." The Lancet. 2022;400(10357):1047-1060. PubMed
  14. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. "Tolerance to Daytime Sedative Effects of H1 Antihistamines." Journal of Clinical Psychopharmacology. 2002;22(5):511-515. PubMed
  15. Goetz DW, Jacobson JM, Murnane JE, et al. "Prolongation of Simple and Choice Reaction Times in a Double-Blind Comparison of Twice-Daily Hydroxyzine Versus Terfenadine." The Journal of Allergy and Clinical Immunology. 1989;84(3):316-322. PubMed
  16. Conen S, Theunissen EL, Van Oers AC, Valiente R, Ramaekers JG. "Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers." Journal of Psychopharmacology. 2011;25(11):1517-1523. DOI
  17. Orriols L, Luxcey A, Contrand B, et al. "Road Traffic Crash Risk Associated With Prescription of Hydroxyzine and Other Sedating H1-Antihistamines: A Responsibility and Case-Crossover Study." Accident Analysis & Prevention. 2017;106:115-121. PubMed
  18. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. "American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults." Journal of the American Geriatrics Society. 2023;71(7):2052-2081. DOI
  19. Simons FE. "Advances in H1-Antihistamines." The New England Journal of Medicine. 2004;351(21):2203-2217. DOI
  20. Bierly JJ, D'Orazio AL. "Hydroxyzine in Impaired Driving Investigations." Journal of Analytical Toxicology. 2025. PubMed
  21. Food and Drug Administration. "Hydroxyzine Hydrochloride Prescribing Information." Updated August 2025. DailyMed
  22. Food and Drug Administration. "Hydroxyzine Hydrochloride Tablets Prescribing Information." Updated June 2026. DailyMed
  23. Morales DR, Macfarlane T, MacDonald TM, et al. "Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis." Pharmacoepidemiology and Drug Safety. 2021;30(4):477-485. DOI
  24. Morrow RL, Mintzes B, Souverein PC, et al. "Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study." Drug Safety. 2022;45(6):623-638. DOI
  25. Ali Z, Ismail M, Khan F, Sajid H. "Association of H1-Antihistamines With Torsade De Pointes: A Pharmacovigilance Study of the Food and Drug Administration Adverse Event Reporting System." Expert Opinion on Drug Safety. 2021;20(1):101-107. PubMed
  26. Chen A, Metzger E, Lee S, Osser D. "A Proposed Algorithm for the Pharmacological Treatment of Generalized Anxiety Disorder in the Older Patient." Journal of Geriatric Psychiatry and Neurology. 2025;38(2):83-97. DOI
  27. Gray SL, Anderson ML, Dublin S, et al. "Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study." JAMA Internal Medicine. 2015;175(3):401-407. PubMed
  28. Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. "Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study." JAMA Internal Medicine. 2019;179(8):1084-1093. PubMed
  29. Richardson K, Fox C, Maidment I, et al. "Anticholinergic drugs and risk of dementia: case-control study." BMJ. 2018;361:k1315. PubMed
  30. Scott AJ, Correa AB, Bisby MA, et al. "Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease: A Systematic Review and Meta-Analysis." JAMA Internal Medicine. 2025. DOI
  31. Bai N, Cao J, Zhang H, Liu X, Yin M. "Digital cognitive behavioural therapy for patients with insomnia and depression: A systematic review and meta-analysis." Journal of Psychiatric and Mental Health Nursing. 2024;31(4):552-566. DOI
  32. Xu D, Li Z, Leitner U, et al. "Efficacy of Remote Cognitive Behavioural Therapy for Insomnia in Improving Health Status of Patients with Insomnia Symptoms: A Meta-analysis." Cognitive Therapy and Research. 2024;48:369-388. DOI
  33. Kishi T, Ikuta T, Sakuma K, et al. "Comparative Effects of Hypnotic Agents on Sleep Architecture and Respiratory Outcomes in Obstructive Sleep Apnea: A Systematic Review and Network Meta-Analysis." Psychiatry and Clinical Neurosciences. 2026. PubMed
  34. Simons KJ, Watson WT, Chen XY, Simons FE. "Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly." Clinical Pharmacology and Therapeutics. 1989;45(1):9-14. PubMed
  35. Staevska M, Gugutkova M, Lazarova C, et al. "Night-time sedating H1-antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial." The British Journal of Dermatology. 2014;171(1):148-154. PubMed
  36. Orzechowski RF, Currie DS, Valancius CA. "Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models." European Journal of Pharmacology. 2005;506(3):257-264. PubMed
Medical Disclaimer: This resource provides clinical context for educational purposes and is not medical advice. In Precision Medicine, the right sleep plan must be matched to your unique history, medications, and goals. Consult Dr. Ash or your own physician before starting, changing, or stopping any prescription medication.
Ashvin Vijayakumar MD (Dr. Ash)

Fishtown Medicine | Treatments

2418 E York St, Philadelphia, PA 19125·(267) 360-7927·hello@fishtownmedicine.com·HSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Off-label sleep dosing is 10 to 25 mg (up to 50 mg) taken 30 to 60 minutes before bed. After QTc and torsades de pointes safety reviews (EMA PRAC 2015; Morales 2021), European and UK regulators capped total daily doses at 100 mg/day in adults and 50 mg/day in older adults.<sup>23</sup><sup>26</sup> Meanwhile, the 2023 AGS Beers Criteria advise avoiding hydroxyzine in adults 65 and older.<sup>18</sup>
Brain histamine H1 receptors adapt quickly to nightly blockade. In crossover testing of first-generation H1 antihistamines (Richardson et al., J Clin Psychopharmacol 2002), sedation was strong on Day 1 and matched placebo by Day 4.<sup>14</sup> Both the VA/DoD 2025 insomnia guideline and the 2023 Beers Criteria cite this rapid tolerance as a key reason antihistamines fail as chronic sleep aids.<sup>5</sup><sup>18</sup>
Yes. Hydroxyzine has a half-life of 20.0 +/- 4.1 hours (Conen et al., J Psychopharmacol 2011).<sup>16</sup> In a highway driving RCT (Conen 2011), 50 mg of hydroxyzine increased lane weaving (SDLP) by +4.7 cm on Day 1 (matching a 0.08% blood alcohol level) and by +2.2 cm on Day 8 (matching a 0.05% blood alcohol level).<sup>16</sup> In a study of 142,771 drivers (Orriols et al., 2017), hydroxyzine raised at-fault crash odds by 67% to 160% (OR 1.67 to 2.60).<sup>17</sup>
Two drug groups matter most: (1) QT-prolonging medications (citalopram, escitalopram, ondansetron, azithromycin, ciprofloxacin, amiodarone, sotalol, haloperidol, quetiapine, methadone), which add to hydroxyzine's risk of QTc prolongation and torsades de pointes (FDA Label 2025/2026; EMA 2015); and (2) sedatives and anticholinergics (alcohol, opioids, benzodiazepines, Z-drugs, bladder antimuscarinics, tricyclics), which add to drowsiness, delirium, and fall risk (Beers 2023).<sup>18</sup><sup>21</sup><sup>22</sup>

Deep-Dive Questions

Across the published literature (Burgazli et al., Hum Psychopharmacol 2023), only 5 studies (207 people total) have tested hydroxyzine for sleep, and zero RCTs have enrolled patients with primary chronic insomnia disorder.<sup>6</sup> The positive studies tested 12 healthy volunteers for one night (Alford 2004), 35 cirrhosis patients for 10 days (Spahr 2007, where 1 patient developed overt hepatic encephalopathy), or PTSD nightmares (Ahmadpanah 2014). Meanwhile, an SSRI/dysthymia trial (Kotan 2015) found hydroxyzine worsened sleep-onset latency (+14.7 min) and cut total sleep time by ~80 minutes.<sup>6</sup><sup>7</sup><sup>8</sup>
Prospective cohort studies (Gray et al., JAMA Intern Med 2015, n = 3,434) and nested case-control analyses (Coupland et al., JAMA Intern Med 2019, 284,343 patients; Richardson et al., BMJ 2018) show a dose-response link between cumulative strong anticholinergic use and incident dementia (HR ~1.54 at highest exposure).<sup>27</sup><sup>28</sup><sup>29</sup> Observational studies cannot fully rule out confounding by indication (since early brain changes can disturb sleep years before diagnosis). Even so, the AGS Beers Criteria (2023) rate hydroxyzine as a strong "Avoid" in older adults.<sup>18</sup>
Both drugs block histamine H1 receptors, yet selectivity depends on the drug and the dose. At 3 to 6 mg, doxepin binds H1 receptors with high selectivity and minimal anticholinergic, adrenergic, or QTc activity.<sup>1</sup> It is backed by placebo-controlled RCTs in chronic insomnia disorder, FDA approval for sleep maintenance, and an AASM 2017 guideline recommendation (Sateia et al., 2017).<sup>1</sup> Hydroxyzine brings strong anticholinergic load and a 20-hour half-life at every sleep dose (25 to 100 mg).

Ready when you are

Start your intake

The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.

Related Intelligence

CBT-I for Chronic Insomnia: Why Sleep Restriction Outlasts Sleeping Pills and When Orexin Blockers Help

CBT-I for Chronic Insomnia: Why Sleep Restriction Outlasts Sleeping Pills and When Orexin Blockers Help

Both the ACP and AASM recommend CBT-I ahead of any sleeping pill because its gains hold at 6 and 12 months. How sleep restriction and stimulus control work, why orexin blockers (DORAs) beat Z-drugs and trazodone when a bridge is needed, and why 0.5 mg timed melatonin beats 5-10 mg bedtime gummies.

Read Deep Dive
Doxepin for Sleep (3 to 6 mg vs. 10 to 150 mg): Trials, H1 Selectivity, and Antihistamine Comparison

Doxepin for Sleep (3 to 6 mg vs. 10 to 150 mg): Trials, H1 Selectivity, and Antihistamine Comparison

Clinical guide to ultra-low-dose doxepin (3 to 6 mg) vs. 10 to 150 mg tricyclic doses, hydroxyzine, and Benadryl: human-brain H1 binding (Kd 0.24 nM), AASM sleep-maintenance trials (WASO -22 to -23 min through Night 85), 2023 Beers Criteria<=6 mg rule, and anticholinergic dementia cohorts.

Read Deep Dive
Gabapentin for Sleep (100-600 mg): Deep Sleep vs. Sleep Apnea

Gabapentin for Sleep (100-600 mg): Deep Sleep vs. Sleep Apnea

Gabapentin for sleep (100-600 mg) boosts Stage N3 deep sleep and cuts night waking, yet 300 mg raises sleep apnea AHI by 84%. Trial data, RLS dosing & risks.

Read Deep Dive

New patients

Talk it through with Dr. Ash.

Share what is weighing on you and what support has or has not helped. Dr. Ash reads every intake personally.

HSA/FSA eligible
No initiation or cancellation fees
No copays
Tell Dr. Ash what’s going on →
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
2418 E York St, Philadelphia, PA 19125(267) 360-7927Primary care in PhiladelphiaHome visits in Greater PhiladelphiaPricing & MembershipGER·O·SPAN: our clinical frameworkDigital Health LiteracyClinical Evidence & Research

Serving Fishtown · Northern Liberties · East Kensington · Olde Richmond · Port Richmond · Old City · Callowhill · Poplar · Center City · Center City West · Art Museum · Bella Vista · Chestnut Hill · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark · Bryn Mawr, PA · Gladwyne, PA · Villanova, PA · Wayne, PA · Cherry Hill, NJ · Haddonfield, NJ · Medford, NJ · Moorestown, NJ · Voorhees, NJ

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • Testosterone (TRT)
  • Sleep Apnea & Low T
  • Andropause
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack
  • Supplement Guides
Care in Philadelphia +
Direct Primary Care in Philadelphia, PAConcierge Medicine in Philadelphia, PAConcierge vs DPC in Philadelphia, PALongevity Medicine in Philadelphia, PAPreventive Care in Philadelphia, PAExecutive Physical in Philadelphia, PAAnnual Physical in Philadelphia, PAHealthspan Optimization in Philadelphia, PAFunctional Medicine in Philadelphia, PASame-Day Sick Visits in Philadelphia, PATestosterone Replacement Therapy in Philadelphia, PAPerimenopause Care in Philadelphia, PAMenopause Care in Philadelphia, PAThyroid Treatment in Philadelphia, PAPCOS Care in Philadelphia, PAGLP-1 Weight Loss in Philadelphia, PAMetabolic Health in Philadelphia, PAHormone Optimization in Philadelphia, PAAdvanced Lipid Testing in Philadelphia, PAVO2 Max Testing in Philadelphia, PADEXA Scan in Philadelphia, PACGM in Philadelphia, PALong COVID Care in Philadelphia, PAChronic Fatigue Treatment in Philadelphia, PAPOTS Treatment in Philadelphia, PAMCAS Treatment in Philadelphia, PALyme Disease Care in Philadelphia, PABrain Fog Treatment in Philadelphia, PASleep Disorders Treatment in Philadelphia, PAStrep Throat Treatment in Philadelphia, PAUTI Treatment in Philadelphia, PASinus Infection Treatment in Philadelphia, PASTI Testing in Philadelphia, PATravel Medicine in Philadelphia, PAPre-Op Clearance in Philadelphia, PASports Club Medicine in Philadelphia, PA

Made it this far? You’re already most of the way there. let’s get started → Dr. Ash reads every word personally.

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical IndependenceCare NetworkResearch & Monographs